Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1681-1700 of 2,120 trials

Gastric Cancer Treatment: GASTRICHIP Trial

We are comparing two surgical treatments for advanced gastric cancer to see if adding chemotherapy during surgery improves survival rates. This study involves patients with specific stages of gastric adenocarcinoma.

Stomach Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Complicated Urinary Tract Infections in Children: Vabomere Study

We are studying the safety and effectiveness of Vabomere for children aged 3 months to under 12 years with complicated urinary tract infections. This research aims to improve treatment options for these young patients.

Complicated Urinary Tract InfectionAcute Pyelonephritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology

Group B Streptococcus Vaccine: GBS NN/NN2 in Pregnant Women

We are studying the GBS NN/NN2 vaccine to see how long the immune response lasts and how safe it is when given as a booster during a new pregnancy. We also want to understand how well antibodies are passed from mothers to their babies.

Group B Streptococcus Neonatal Sepsis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboGynecology and ObstetricsInfectious Diseases

Stage IIIA/B NSCLC: New Immunotherapy and Chemotherapy Approach

We are studying a new treatment combining immunotherapy and chemotherapy for patients with resectable stage IIIA/B non-small cell lung cancer. The trial aims to see if this approach improves survival and quality of life compared to standard treatments.

Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Post-COVID-19 Condition: Plitidepsin Study

We are investigating whether plitidepsin can improve health outcomes for adults with post-COVID-19 Condition. The study will compare its effects to a placebo on symptoms and overall well-being.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinologyGastroenterologyHematologyInfectious DiseasesInternal MedicineNeurologyPsychiatryPulmonologyRheumatology

Acute Bacterial Skin Infections: IV Oritavancin for Kids

We are studying a single-dose intravenous medication for children with acute bacterial skin infections. The trial aims to assess its safety and how well it works compared to existing treatments.

Acute Bacterial Skin and Skin Structure Infection>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyPediatrics

Soft Tissue Sarcoma: Trabectedin with tTF-NGR

We are studying a new treatment combining trabectedin with tTF-NGR for patients with advanced soft tissue sarcoma. The goal is to see if this combination helps patients live longer without disease progression compared to trabectedin alone.

Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Eculizumab for Hypertensive Emergency-Associated Kidney Condition

We are studying whether Eculizumab can improve kidney function in patients with a severe kidney condition linked to high blood pressure. This trial will help us understand its effects on dialysis needs and overall health.

Atypical Hemolytic Uremic Syndrome (aHUS)1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Immune Thrombocytopenia: Dexamethasone vs. IVIg

We are studying whether oral dexamethasone is as effective as intravenous immunoglobulin combined with prednisone for adults with immune thrombocytopenia experiencing bleeding. This research may help identify a more convenient treatment option.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Lyell Syndrome: Mesenchymal Stromal Cells Treatment

We are testing a new treatment using mesenchymal stromal cells for patients with Lyell syndrome. The study aims to see if this treatment can help improve skin healing and overall health.

Lyell Syndrome>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyHematology

Sepsis Treatment: Hydrocortisone and Fludrocortisone Study

We are investigating whether a combination of hydrocortisone and fludrocortisone can improve outcomes for adults with sepsis in the ICU. This study aims to see if it helps reduce death or ongoing organ issues compared to a placebo.

Sepsis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Multiple Myeloma: Elranatamab and Lenalidomide Study

We are testing a new combination treatment for newly diagnosed multiple myeloma to see if it works better than standard therapies. The study aims to evaluate its effectiveness and safety during different treatment phases.

Multiple Myeloma3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Neonatal Hypoxic Ischemic Encephalopathy: Cord Blood Stem Cell Treatment

We are studying the safety and feasibility of using a baby's own cord blood stem cells to treat neonatal hypoxic ischemic encephalopathy. The trial also looks at how this treatment may help prevent long-term neurological problems.

Neonatal Hypoxic-Ischaemic Encephalopathy>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPediatrics

Sedation Study: Remimazolam vs. Midazolam for GI Endoscopy

We are comparing two sedation medications to see which one helps patients recover faster after upper GI endoscopy. We’ll also look at patient satisfaction and any side effects.

Healthy ParticipantsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal MedicineOtolaryngology

Luspatercept for Anemia in Lower-Risk MDS Patients

We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.

Myelodysplastic Syndromes (MDS)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematology

Liver Cancer: Tislelizumab Immunotherapy Study

We are testing a new immunotherapy for patients with liver cancer and moderate liver function. The study aims to see if it can improve treatment outcomes and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyOncology

Beta-Lactam Antibiotics: Precision Dosing in Critically Ill Children

We are studying a new dosing method for beta-lactam antibiotics in critically ill children to see if it helps them reach treatment goals faster than standard dosing. This may also help reduce their time in the hospital.

Systemic Infections>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

Urothelial Cancer: DDR Gene Testing for Chemotherapy Response

We are studying whether changes in DDR genes can help predict how well patients with advanced urothelial cancer respond to platinum-based chemotherapy. This may lead to better treatment decisions for patients based on their genetic profile.

Metastatic or Locally Advanced Urothelial Cancer1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Obstructive Colon Cancer: Neoadjuvant Chemotherapy Study

We are studying whether two chemotherapy regimens can improve treatment outcomes for patients with obstructive colon cancer after colostomy. The goal is to see if starting chemotherapy before surgery leads to better recovery and survival rates.

Colon Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Inflammatory Disorders: New Imaging Tracer 18F-AlF-FAPI-74

We are studying a new imaging tracer to see if it can better diagnose inflammatory disorders compared to the standard tracer. This trial includes patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis.

Fever of Unknown OriginIgG4-Related DiseaseAxial Spondyloarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyRheumatology